CSTL Stock Overview
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers.
Castle Biosciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$27.54|
|52 Week High||US$68.65|
|52 Week Low||US$15.58|
|1 Month Change||4.32%|
|3 Month Change||6.74%|
|1 Year Change||-57.67%|
|3 Year Change||38.53%|
|5 Year Change||n/a|
|Change since IPO||28.69%|
Recent News & Updates
Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Castle Biosciences, Inc. ( NASDAQ:CSTL ) shareholders will have a reason to smile today, with the analysts making...
|CSTL||US Healthcare||US Market|
Return vs Industry: CSTL underperformed the US Healthcare industry which returned 13.9% over the past year.
Return vs Market: CSTL underperformed the US Market which returned -18.8% over the past year.
|CSTL Average Weekly Movement||9.7%|
|Healthcare Industry Average Movement||7.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: CSTL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: CSTL's weekly volatility (10%) has been stable over the past year.
About the Company
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions.
Castle Biosciences, Inc. Fundamentals Summary
|CSTL fundamental statistics|
Is CSTL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CSTL income statement (TTM)|
|Cost of Revenue||US$22.73m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.69|
|Net Profit Margin||-40.37%|
How did CSTL perform over the long term?See historical performance and comparison